Latest News and Press Releases
Want to stay updated on the latest news?
-
LAS VEGAS, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc. (VIVK), a technology and asset acquisition company with a focus in the area of natural resources, today announced that Matt Nicosia, Chief...
-
Expected to Commence Operations in Utah in Q1 2019 LAS VEGAS, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc. (VIVK), a technology and asset acquisition company with a focus in the area of natural...
-
Major Inflection Point Reached and Targeting to Have 10 Remediation Processing Centers in Operation LAS VEGAS, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc. (VIVK), a technology and asset...
-
Seeking to Expand Multi-Patent Technology Portfolio LAS VEGAS, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc. (VIVK), a technology and asset acquisition company with a focus in the area of...
-
Initial Contract Worth up to $2 Million Expected to Start in AugustLong-Term Potential of Tens of Millions of Dollars Over Several Years LAS VEGAS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc....
-
Focused on Increasing Awareness and Enhancing Shareholder Value LAS VEGAS, July 12, 2018 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTC PINK:VIVK), a technology and asset acquisition company with a...
-
IRVINE, Calif., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that it has received an Letter of Intent for $3 Million in investment capital from a private investment...
-
IRVINE, Calif., Jan. 3, 2011 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) released the following shareholder update from management. The previously announced Regeneca International Inc. stock...
-
IRVINE, Calif., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that the Company has filed an application with FINRA for the distribution of the previously announced stock...
-
IRVINE, Calif., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) today announced the executive offices of the Company have been relocated to Irvine, California. Current research will remain...